基本信息
浏览量:445
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
His work has focused on clinical and research applications of the tracer principle for molecular imaging and targeted therapy in oncology. He has developed key insights in the pathophysiology of disease and successfully translated nascent discoveries into clinical applications supporting not only the diagnosis of disease, but also the use of targeted radiotherapy in humans. Dr. Larson produced a tremendous body of work over the course of his career, as evinced by the more than 700 peer-reviewed research articles to his credit.
With respect to his work on the invention of for oncology, an especially noteworthy example that influenced clinical care is the development of Tc-99m sulfur colloid, which was perhaps the earliest of the diagnostic nanoparticles and has been used for five decades in the United States, Europe, and Asia. Initially used for organ (liver) and bone marrow imaging, it is now also used for sentinel node imaging, especially in breast cancer and melanoma.
Dr. Larson was a pioneer in recognizing and generating acceptance of fluorodeoxyglucose (FDG) positron emission tomography (PET) as a measure of tumor glycolysis and as a critically important tool in cancer care. He showed the feasibility of PET imaging of tumor glycolysis by providing the initial demonstration of FDG uptake in an animal tumor. Dr. Larson also made important strides in radiopharmacology of molecular imaging. For example, he led the first-in-man use of PET imaging of a positron-labeled radioantibody for in vivo dosimetry of targeted radioimmunotherapy. Dr. Larson is a luminary in his field, and his work has had a profound impact on the trajectory of nuclear medicine and the care of patients with cancer around the world.
With respect to his work on the invention of for oncology, an especially noteworthy example that influenced clinical care is the development of Tc-99m sulfur colloid, which was perhaps the earliest of the diagnostic nanoparticles and has been used for five decades in the United States, Europe, and Asia. Initially used for organ (liver) and bone marrow imaging, it is now also used for sentinel node imaging, especially in breast cancer and melanoma.
Dr. Larson was a pioneer in recognizing and generating acceptance of fluorodeoxyglucose (FDG) positron emission tomography (PET) as a measure of tumor glycolysis and as a critically important tool in cancer care. He showed the feasibility of PET imaging of tumor glycolysis by providing the initial demonstration of FDG uptake in an animal tumor. Dr. Larson also made important strides in radiopharmacology of molecular imaging. For example, he led the first-in-man use of PET imaging of a positron-labeled radioantibody for in vivo dosimetry of targeted radioimmunotherapy. Dr. Larson is a luminary in his field, and his work has had a profound impact on the trajectory of nuclear medicine and the care of patients with cancer around the world.
研究兴趣
论文共 1036 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
The Journal of Nuclear Medicineno. 9 (2023): 1439-1445
crossref(2023)
David Ulmert,Michael J. Evans,Jason P. Holland,Samuel L. Rice,John Wongvipat,Kim Pettersson, Per-Anders Abrahamsson,Peter T. Scardino,Steven M. Larson,Hans Lilja, Jason S. Lewis,Charles L. Sawyers
crossref(2023)
crossref(2023)
THERANOSTICSno. 15 (2023): 5469-5482
Journal of nuclear medicine : official publication, Society of Nuclear Medicineno. 9 (2023): 1439-1445
crossref(2023)
crossref(2023)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn